Naunyn-Schmiedebergs Archives of Pharmacology 1997-05-01

Cardiac electrophysiological actions of NS-21 and its active metabolite, RCC-36, compared with terodiline.

S Hayashi, T Natsukawa, C Suma, Y Ukai, Y Yoshikuni, K Kimura

Index: Naunyn Schmiedebergs Arch. Pharmacol. 355(5) , 651-8, (1997)

Full Text: HTML

Abstract

Terodiline, an anticholinergic drug with a Ca2+ blocking action, is thought to be associated with torsade de pointes, a serious ventricular tachycardia. NS-21 is a newly developed drug for the treatment of urinary frequency and urinary incontinence and it has pharmacological properties similar to those of terodiline. It remains unknown, however, whether NS-21 and its active metabolite, RCC-36, have any proarrhythmic activity. The electrophysiological properties of NS-21 and RCC-36 were examined in guinea pig ventricular myocytes and were compared with those of terodiline using the whole-cell patch-clamp technique. NS-21, RCC-36 and terodiline inhibited L-type Ca2+ currents in a concentration-dependent manner with IC50 values of 27.0, 27.0 and 33.5 microM, respectively. At a concentration of 10 microM, terodiline inhibited both the time-dependent current and the tail current of the delayed rectifier K+ current, with the latter being significantly inhibited at voltages more positive than +10 mV. In contrast, NS-21 and RCC-36 had almost no effect on either of these currents. Terodiline also inhibited the inward rectifier K+ current significantly at voltages more negative than -100 mV, whereas NS-21 and RCC-36 had little effect. If the proarrhythmic activity of terodiline resulted primarily from the combined inhibition of K+ and Ca2+ currents, one might expect that NS-21 and RCC-36, which inhibit L-type Ca2+ currents without affecting either the delayed rectifier K+ current or the inward rectifier K+ current, would not share the proarrhythmic activities of terodiline.


Related Compounds

  • Terodiline hydroch...

Related Articles:

Action potentials, contraction, and membrane currents in guinea pig ventricular preparations treated with the antispasmodic agent terodiline.

1999-09-01

[J. Pharmacol. Exp. Ther. 290(3) , 1417-26, (1999)]

Comparison of the effects of NS-21 and terodiline on the QTc interval in dogs.

1998-01-01

[Gen. Pharmacol. 30(1) , 137-42, (1998)]

CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system.

2000-07-01

[Br. J. Clin. Pharmacol. 50(1) , 77-80, (2000)]

Inhibition of cardiac inward-rectifier K+ current by terodiline.

1999-07-01

[Eur. J. Pharmacol. 370(3) , 319-27, (1999)]

Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dog.

2001-01-01

[Xenobiotica 31(8-9) , 633-50, (2001)]

More Articles...